potentially very major news with moderna s vaccine and young children. the only group still not eligible for any covid vaccine, new data that you ve all released from your studies of the vaccine in children under 6 years old, showing a strong immune response but also in the data, it shows only about 40% effective in preventing symptomatic covid. can you talk me through what you re seeing in your studies and why then about 40% is good enough? yeah. so kate, first of all, i would say that as a dad and physician, what we always look at first is safety and the safety results in this study, 7,000 children were involved. five of them got the vaccine. a quarter dose. 25 micrograms given a month apart. safety was very reassuring. exactly what we ve seen in the past and rates of high temperature, high fever above 40 degrees centigrade. 0.2% of the kids. that s very reassuring. what we wanted to do is show
04.04.2022 - GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) - Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene . Seite 1
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
/PRNewswire/ Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in.